Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）

Phase 3

Innovent Biologics Inc/ADR (IVBXF)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q4 '26

IVBXFPhase 3$19.2B

Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI） Phase 3 Est. Readout

Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）• Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma464

Q4 2026~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

View Full Landscape

Drug Information

Target Indication

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical Trial

NCT06238843

Last updated: 6/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

IVBXF

Innovent Biologics Inc/ADR

Biotechnology•North America•NASDAQ

Related Pipeline

IBI301 plus CHOPPhase 3

Diffuse, Large B-Cell, Lymphoma

PicankibartPhase 3

Plaque Psoriasis

DocetaxelPhase 3

HER2-positive Breast Cancer

FebuxostatPhase 3

Gout

IBI311Phase 3

Thyroid Eye Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts